November 12th 2024
The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.
Exploring the efficacy and safety of rotavirus vaccines
July 12th 2021Rotavirus can lead to gastrointestinal concerns that can be hazardous to children when rehydration isn’t readily available, which means that a safe, effective vaccine could be life-saving. A meta-analysis examines the safety and efficacy of available immunizations.
Using education to tackle parents' concerns about the flu shot
July 7th 2021Educating families to alleviate fear in pediatric populations regarding the flu vaccine will improve the vaccination rate and protect high-risk children. Due to the negative effects of the flu in children with diabetes, it is vital that at-risk youth be vaccinated.
ISV congress offers vaccine updates and information on hypersensitivity
June 4th 2021The last meeting of the COVID-19 vaccine congress from the International Society for Vaccines (ISV) provided information on the hypersensitivity events tied to mRNA vaccines as well as the most recent information on the Janssen and Novavax vaccines.